Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Nature Immunology
|
October 22, 2008
Activated pDCs: open to new antigen-presentation possibilities
Tineke van den Hoorn, Jacques Neefjes
Current Opinion in Immunology
|
November 30, 2010
Routes to manipulate MHC class II antigen presentation
Tineke van den Hoorn, Petra Paul, Marlieke L M Jongsma, et al.
Journal of Cell Science
|
February 4, 2012
Dynamics within tetraspanin pairs affect MHC class II expression
Tineke van den Hoorn, Petra Paul, Lennert Janssen, et al.
Molecular Biology of the Cell
|
November 14, 2009
Mobility, microtubule nucleation and structure of microtubule-organizing centers in multinucleated hyphae of Ashbya gossypii
Claudia Lang, Sandrine Grava, Tineke van den Hoorn, et al.
British Journal of Clinical Pharmacology
|
September 16, 2020
Animal-free applications in the development of cell-based therapies
Peter van Meer, Peter Theunissen, Tineke van den Hoorn, et al.
British Journal of Clinical Pharmacology
|
August 14, 2020
Mining scientific advice reports on cell-based products: Insight into the nonclinical development program
Tineke van den Hoorn, Tahira Nakchedi, A Charlotte M T de Wolf, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
March 26, 2021
Physiologically Relevant Estrogen Receptor Alpha Pathway Reporters for Single-Cell Imaging-Based Carcinogenic Hazard Assessment of Estrogenic Compounds
Britt Duijndam, Annabel Goudriaan, Tineke van den Hoorn, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA
|
March 21, 2022
Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals
Britt Duijndam, Massimo Tedeschi, Wanda van der Stel, et al.
The European Respiratory Journal
|
October 9, 2025
The European Medicines Agency's review of elexacaftor/tezacaftor/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I <i>CFTR</i> variants
Catherine Drai, Hanneke J van der Woude, Anne J Lexmond, et al.
Cell
|
April 5, 2011
A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation
Petra Paul, Tineke van den Hoorn, Marlieke L M Jongsma, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Nature Immunology
|
October 22, 2008
Activated pDCs: open to new antigen-presentation possibilities
Tineke van den Hoorn, Jacques Neefjes
Current Opinion in Immunology
|
November 30, 2010
Routes to manipulate MHC class II antigen presentation
Tineke van den Hoorn, Petra Paul, Marlieke L M Jongsma, et al.
Journal of Cell Science
|
February 4, 2012
Dynamics within tetraspanin pairs affect MHC class II expression
Tineke van den Hoorn, Petra Paul, Lennert Janssen, et al.
Molecular Biology of the Cell
|
November 14, 2009
Mobility, microtubule nucleation and structure of microtubule-organizing centers in multinucleated hyphae of Ashbya gossypii
Claudia Lang, Sandrine Grava, Tineke van den Hoorn, et al.
British Journal of Clinical Pharmacology
|
September 16, 2020
Animal-free applications in the development of cell-based therapies
Peter van Meer, Peter Theunissen, Tineke van den Hoorn, et al.
British Journal of Clinical Pharmacology
|
August 14, 2020
Mining scientific advice reports on cell-based products: Insight into the nonclinical development program
Tineke van den Hoorn, Tahira Nakchedi, A Charlotte M T de Wolf, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
March 26, 2021
Physiologically Relevant Estrogen Receptor Alpha Pathway Reporters for Single-Cell Imaging-Based Carcinogenic Hazard Assessment of Estrogenic Compounds
Britt Duijndam, Annabel Goudriaan, Tineke van den Hoorn, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA
|
March 21, 2022
Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals
Britt Duijndam, Massimo Tedeschi, Wanda van der Stel, et al.
The European Respiratory Journal
|
October 9, 2025
The European Medicines Agency's review of elexacaftor/tezacaftor/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I <i>CFTR</i> variants
Catherine Drai, Hanneke J van der Woude, Anne J Lexmond, et al.
Cell
|
April 5, 2011
A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation
Petra Paul, Tineke van den Hoorn, Marlieke L M Jongsma, et al.
Page
of 2